What is CJC-1295 and what is it used for?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that prompts the pituitary to release growth hormone, raising GH and IGF-1. It is not FDA-approved. It's used off-label, mainly through anti-aging and wellness clinics and the gray market, for sleep, recovery, and body composition — and it is almost always combined with ipamorelin, a separate GH secretagogue, for a complementary effect.

What's the difference between CJC-1295 with DAC and without DAC?

CJC-1295 'with DAC' (drug affinity complex) is engineered to last much longer in the body, producing a sustained elevation of growth hormone over days. CJC-1295 'without DAC' — often called mod GRF 1-29 — is short-acting and produces a more pulsatile, brief GH release that some consider closer to the body's natural rhythm. The long-acting DAC version raises a specific concern: sustained, non-pulsatile GH elevation is less physiologic than the body's normal pulses, which matters for the IGF-1 and glucose effects.

Is CJC-1295 always used with ipamorelin?

Not always, but very commonly — 'CJC/Ipa' is one of the most popular peptide combinations, often sold pre-mixed in a single vial. CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor secretagogue) raise GH through different, complementary mechanisms. But combining them is a stack: you can't introduce one at a time, can't isolate which causes a benefit or a reaction, and you compound the growth-hormone-axis effects. That's worth understanding before using a combined product.

What are the risks of CJC-1295?

Because it raises growth hormone and IGF-1, CJC-1295 carries the core GH-axis concerns: IGF-1 elevation is a cell-proliferation (cancer-signaling) consideration, and growth hormone can raise blood glucose and worsen insulin sensitivity. Water retention, numbness/tingling, headache, and injection-site reactions are also reported. The long-acting DAC version's sustained GH elevation may amplify these. It is not FDA-approved, is usually stacked (compounding risk), and gray-market product is of unverified purity.

CJC-1295 vs sermorelin — what's the difference?

Both are GHRH analogs that stimulate the pituitary to release growth hormone. Sermorelin is shorter-acting and has real medical lineage (it was once FDA-approved). CJC-1295 was engineered for a longer duration, especially the DAC version, which sustains GH elevation rather than preserving the body's natural pulses. Both share the same GH-axis risk profile; the main practical difference is duration and how 'physiologic' the GH release is.

CJC-1295: The GHRH Peptide Stacked With Ipamorelin

A long-acting growth-hormone-releasing peptide that’s almost always sold paired with ipamorelin. Here’s the honest picture: the two forms (with DAC vs without), what the evidence supports, why it’s really a stack, and the GH-axis risks.

GHRH analog

Stimulates your own GH release

DAC / no-DAC

Long-acting vs pulsatile forms

Usually stacked

The “CJC” in CJC/Ipa

↑ GH / IGF-1

Its mechanism is also its main risk

The one-sentence version: CJC-1295 is a GHRH analog that raises growth hormone; it comes in a long-acting (DAC) and a short-acting (no-DAC / mod GRF 1-29) form, it’s almost always combined with ipamorelin (which makes it a stack), it’s not FDA-approved, the wellness benefits are weakly evidenced in healthy adults, and it carries the same IGF-1 and glucose cautions as other GH-raising compounds.

What CJC-1295 Is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Like sermorelin, it signals the pituitary to release the body’s own growth hormone — raising GH and downstream IGF-1. What sets CJC-1295 apart is engineering for duration.

With DAC vs. Without DAC — the Key Distinction

Form	How it behaves	The tradeoff
CJC-1295 with DAC	“Drug affinity complex” makes it long-acting — sustained GH elevation over days	Convenient (less frequent dosing), but sustained, non-pulsatile GH is less physiologic, which may amplify IGF-1/glucose effects
CJC-1295 without DAC (mod GRF 1-29)	Short-acting — a brief, more pulsatile GH release	Closer to the body’s natural rhythm; requires more frequent dosing

The body normally releases GH in pulses, and that pulsatility appears to matter. The long-acting DAC version trades the natural pulse for convenience and a steady elevation — which is exactly why some prefer the no-DAC form despite the more frequent dosing.

Why Buying CJC-1295 Usually Means Buying a Stack

CJC-1295 is rarely used alone. It’s almost always combined with ipamorelin — a ghrelin-receptor secretagogue — because the two raise GH through different, complementary mechanisms. “CJC/Ipa” is one of the most popular peptide combinations, frequently sold pre-mixed in one vial.

Be clear-eyed: a pre-mixed CJC/Ipa vial is a stack, not a single compound. You can’t introduce one at a time, can’t isolate which one causes a benefit or a reaction, and you compound the growth-hormone-axis effects. Before using a combined product, read the risks of stacking peptides and the ipamorelin guide.

What the Evidence Supports

Demonstrated — CJC-1295 raises GH and IGF-1

The core pharmacologic effect — increasing growth hormone and IGF-1 — is established, particularly for the long-acting DAC version’s sustained elevation.

Limited — wellness outcomes in healthy adults weakly evidenced

The popular goals — better sleep, recovery, body composition, “anti-aging” — rest mostly on the GH-raising mechanism and anecdote, not robust controlled outcome data in otherwise-healthy adults. The GH effect is real; the downstream benefits people are sold are not well established.

The Risks the Marketing Skips

IGF-1 elevation and cancer signaling. Raising IGF-1 is a cell-proliferation consideration; active malignancy is a reason to avoid it, and cancer history makes it a clinician-level decision.
Glucose and insulin. Growth hormone can raise blood glucose and worsen insulin sensitivity — relevant for diabetes/prediabetes, and the long-acting DAC form’s sustained elevation may amplify this.
Water retention, numbness/tingling, headache, injection-site reactions are reported.
Stacking risk. Because it’s almost always combined with ipamorelin, GH-axis effects and quality/attribution problems compound.
Pituitary tumors are an absolute contraindication. As a GH secretagogue, CJC-1295 stimulates the pituitary’s growth-hormone cells, so a history of a pituitary adenoma — even a stable, treated one — is a hard reason not to use it, because the stimulation can risk tumor regrowth. An endocrinologist’s call, not a forum’s.
Unregulated supply. Not FDA-approved; gray-market product is of unverified purity (see where to get peptides tested).

The Honest Bottom Line

CJC-1295 is a real, long-acting GH-releasing peptide, and the DAC-vs-no-DAC choice is a genuine pharmacologic decision about how natural you want the GH release to be. But it’s not approved, the wellness benefits are weakly evidenced in healthy adults, it’s almost always used as a stack with ipamorelin (with the added risks that brings), and it carries the same IGF-1 and glucose cautions as any GH-raising compound. If you’re considering it, that’s a clinician conversation with screening and lab monitoring — not a pre-mixed vial from an unverified source.

Frequently Asked Questions

What is CJC-1295 used for?

It’s a GHRH analog used off-label (clinics and gray market) for sleep, recovery, and body composition, almost always combined with ipamorelin. Not FDA-approved.

With DAC vs without DAC?

With DAC is long-acting (sustained GH); without DAC (mod GRF 1-29) is short-acting and more pulsatile, closer to the body’s natural rhythm.

Is it always used with ipamorelin?

Very commonly — “CJC/Ipa” is a top combo, often pre-mixed. That makes it a stack, with stacked risks and no ability to isolate one compound.

What are the risks?

The GH-axis risks (IGF-1/cancer signaling, glucose), plus water retention, tingling, headache, and injection reactions — compounded by stacking and unverified gray-market supply.

CJC-1295 vs sermorelin?

Both are GHRH analogs. Sermorelin is shorter-acting with real medical lineage; CJC-1295 (especially DAC) is engineered to last longer, sustaining GH rather than preserving natural pulses. Same GH-axis risk profile.

This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. CJC-1295 affects the growth-hormone axis and is not FDA-approved; decisions about it — especially in combination with other compounds (such as ipamorelin) or medications — should be made with a licensed clinician who can screen for contraindications (including cancer history and glucose status) and monitor appropriate labs. Research peptides sold “for research use only” are not approved for human use. Verify current information before relying on it. Current as of June 20, 2026.